PCA 50982
Latest Information Update: 23 Nov 2006
Price :
$50 *
At a glance
- Originator Alter
- Class Anti-ischaemics; Ischaemic heart disorder therapies
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Angina pectoris; Myocardial ischaemia
Most Recent Events
- 01 Sep 1998 No-Development-Reported for Angina pectoris in Spain (Unknown route)
- 01 Sep 1998 No-Development-Reported for Myocardial ischaemia in Spain (Unknown route)
- 25 Oct 1995 Preclinical development for Angina pectoris in Spain (Unknown route)